An update to active surveillance recommendations has some physicians concerned. The National Comprehensive Cancer Network (NCCN) recently updated its guidelines for the treatment of prostate cancer, 1 ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the ...

Data from a nationwide German registry with data from nearly 3,000 long-term survivors of radical prostatectomy sheds light on how frailty impacts the lives they lead. Treat or observe? Dr. Joseph ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...

PLYMOUTH MEETING, PA [October 9, 2024] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers in the United States—announces a renewed collaboration with the ...